Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 801–900 of 1,001
Ilyin, N. P., Nabiullin, A. D., Kozlova, A. D., Kupriyanova, O. V., Shevyrin, V. A., Gloriozova, T. A., Filimonov, D. A., Lagunin, A. A., Galstyan, D. S., Kolesnikova, T. O., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00017 · Cited by 5
The cyclical revival of psychedelics in psychiatric treatment
Appiani, F. J., & Caroff, S. N. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2368725 · Cited by 5
Mastelić, T., Marasović, T. B., Žuljević, M. F., Ercegovac, M. S., Kaliterna, M., Pleić, N., Vukorepa, D., Topić, J., Cvitanović, M., Lasić, D., et al. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2370343 · Cited by 5
“…of psychedelics and antidepressants, and the lack of monitoring of the duration of positive effects (Bender and Hellerstein 2022; Breeksema et al. 2022; Carhart-Harris et al. 2021; Gukasyan et al. 2023; Hovmand et al. 2023; IsHak et al. 2023; Kisely et al. 2023; Ko et al. 2023; Nayak et al. 2023).”
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Seragnoli, F., Geo, M., Entela, M., Bachmann, S., Rabitti, E., Cavuto, S., Dubus, Z., Penzenstadler, L. E., Thorens, G., Billieux, J., et al. (2024) · Clinical Case Reports · doi:10.1002/ccr3.9305 · Cited by 7
“Several recent randomized and controlled clinical trials demonstrate the therapeutic effectiveness of psychedelics in various contexts, in particular in the area of depression, 16 anxiety, 17 addiction, 18 and palliative care.”
BackgroundHighly efficient synthesis of lysergic acid using engineered budding yeast
Wu, N., Yao, M., Xiao, W., Wang, Y., & Yuan, Y. (2024) · Green Chemistry · doi:10.1039/d4gc03756a · Cited by 5
The Psychedelic Renaissance: A Catholic Perspective
Carroll, T. (2024) · The Linacre Quarterly · doi:10.1177/00243639241274818 · Cited by 5
“Interestingly, these results are similar to the NNT of 6 that resulted from a meta-analysis of RCTs using LSD to treat AUD published between 1966 and 1970 (Krebs and Johansen 2012).”
InfluentialEvaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective
Marazziti, D., Weiss, F., Gurrieri, R., Russomanno, G., Gambini, M., Magnesa, A., Coccoglioniti, A., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2445016 · Cited by 5
“A head-to-head phase 2 trial comparing escitalopram with psilocybin did not detect any statistical difference in primary outcomes at 6 weeks, but all secondary measures tended to favor psilocybin, including scales related to functional disability and global mental wellbeing [156].”
Psychedelics in Psychiatry: Oh, What A Trip!
Fonzo, G. A., Nemeroff, C. B., & Kalin, N. H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241025 · Cited by 5
Henry, J. S., Giribaldi, B., Nutt, D. J., Erritzøe, D., Carhart-Harris, R. L., & Lyons, T. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.003 · Cited by 5
Self-citationNew antidepressants: New day or false dawn?
Jelen, L. A., & Young, A. H. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.07.004 · Cited by 5
Bienemann, B., Barbosa, A. R., da Cruz, L. V. M., Multedo, M., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2226414 · Cited by 5
“Psilocybin has been shown to be effective against treatment-resistant depression in randomized placebo controlled studies (Luoma et al. 2020), and in a head-to-head comparison it has shown better but not statistically superior results to escitalopram (Carhart-Harris et al. 2021).”
BackgroundBhatele, P., Dwivedi, R., Kalaivani, M., Sarangi, S. C., Singh, R. K., Vibha, D., Elavarasi, A., Sagar, R., Chandra, P. P., & Tripathi, M. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2023.109352 · Cited by 5
Ólafsson, R. P., Kvaran, K., Ketilsdóttir, K., Hallgrímsdóttir, K., Sigurðsson, E. L., & Sigurðsson, E. (2023) · Læknablaðið · doi:10.17992/lbl.2023.11.766 · Cited by 5
Vilca-Melendez, S., Uthaug, M. V., & Griffin, J. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742856 · Cited by 5
Einstellungen von Expertinnen und Experten für psychische Gesundheit gegenüber Psilocybin
Schmidt, C., Wolff, M., Gründer, G., & Jungaberle, H. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1846-1161 · Cited by 6
“1177/0269881114548296 [7] Carhart-Harris R, Giribaldi B, Watts R et al.”
BackgroundEmerging drugs for the treatment of major depressive disorder
Hong, J., Vernon, D., Kunovac, J. L., & Stahl, S. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2117297 · Cited by 5
“showed that psilocybin was just as effective as escitalopram in the primary endpoint and had improved outcomes in secondary endpoints [33,34].”
BackgroundResultBarber, M., Gardner, J., & Carter, A. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100202 · Cited by 5
Carlier, J., Malaca, S., Huestis, M. A., Tagliabracci, A., Tini, A., & Busardò, F. P. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2166826 · Cited by 5
“US Federal Drug Administration (FDA) granted psilocybin ‘breakthrough therapy’ designation in 2018, accelerating the process of approval as a medication [1,4,5].”
BackgroundA review of psilocybin: chemistry, clinical uses and future research directions
Milliken, E. J. T., Galettis, P., & Martin, J. (2023) · Australian Journal of Chemistry · doi:10.1071/ch23010 · Cited by 5
Legalization of Psychedelic Substances
Marks, M. (2021) · JAMA · doi:10.1001/jama.2021.19366 · Cited by 5
Psilocybin for Treatment-Resistant Depression
Roméo, B., Dervaux, A., & Benyamina, A. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2215459 · Cited by 6
Schuler, H., Zhou, D., Savignac, C., Cvetkovska, V., Tse, Y.-C., Meccia, J., Lopez, J., Harutyunyan, A. S., Ragoussis, J., Bzdok, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.08.631940 · Cited by 5
“Psilocybin also exerts sustained therapeutic effects in disorders including depression, anxiety and alcohol use disorder 1–3,5– 7 .”
Kettner, H., Roseman, L., Gazzaley, A., Carhart-Harris, R. L., & Pasquini, L. (2024) · Research Square · doi:10.21203/rs.3.rs-3977169/v1 · Cited by 5
“…associated with an increased incidence of adverse respiratory and gastrointestinal events, as well as emotional blunting when compared to placebo (Banerjee et al., 2011; Carhart-Harris et al., 2021; Rosenberg et al., 2010), highlighting the need for improved treatments for affective symptoms in OA.”
BackgroundSelf-citationLouie, E., Towers, E., Morse, A. R., Watt, J., Bryant, Z., Haber, P., & Morley, K. C. (2025) · International Journal of Mental Health Nursing · doi:10.1111/inm.70010 · Cited by 4
Cirillo, M. A. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251321040 · Cited by 4
Richard, J., Scott, J., Nayak, S. M., Sepeda, N. D., Lowe, M. X., Jackson, H., & Garcia‐Romeu, A. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01489-z · Cited by 5
“…exploring psilocybin’s potential effectiveness for treating various health conditions (Madden et al., 2024) including major depressive disorder (Carhart-Harris et al., 2021; Goodwin et al., 2022, 2025; Haikazian et al., 2023; Raison et al., 2023) and cancer-related existential distress or…”
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs
Acero, V. P., Flatt, T. A., Gooch, P. M., Gaughan, S. J., Levin, A. W., & Davis, A. K. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2515866 · Cited by 4
The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin
Zhang, M., Zhai, H., Yang, L., Li, H., & Wang, X. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00324 · Cited by 4
Garrigosa, M. S., Perl, Y. S., Kringelbach, M. L., Erritzøe, D., Nutt, D. J., Carhart-Harris, R. L., Vohryzek, J., & Deco, G. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15391 · Cited by 6
“20,46 Notably, neu-rostimulation combined therapy has largely been studied with SSRIs rather than psychedelics, with some studies finding that SSRIs like citalopram enhance the neuroplastic after-effects of anodal tDCS. 65,66…”
Self-citationRodan, S.-C., Meez, N., Lloyd-Hurwitz, S., Bedoya‐Pérez, M. A., Suraev, A. S., Sommer, N., Greenstien, K., Maguire, S., & McGregor, I. S. (2025) · Journal of Eating Disorders · doi:10.1186/s40337-025-01328-5 · Cited by 5
“…of psilocybin-assisted psychotherapy have obtained success in treating a wide range of treatment-refractory conditions, including treatment-resistant depression, major depressive disorder (MDD) [6–10], psychological distress in life-threatening illness [11–13], and substance dependence [14, 15].”
Kheirkhah, M., Mcdonald, N., Aepfelbacher, J., Rengasamy, M. L., Shivanekar, S. P., Spotts, C., Cooper, I., Baumeister, A., Bell, E., Do-Nguyen, K., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1642025 · Cited by 5
“This approach was inspired by the responder/ remitter analysis framework used by Carhart-Harris and colleagues (35).”
Richardson, B., Inserra, A., Pileggi, M., Prud’Homme, T., Bruno, V., Wan-Yan-Chan, D., Shareghi-Ghahreman, I., Nasini, S., Strand, T., Leyton, M., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111522 · Cited by 4
Ekoh, F., Rerrie, S., Angud, J., & Mirabelli, E. (2025) · Psychoactives · doi:10.3390/psychoactives4040039 · Cited by 4
Allen, J., Sun, M., Baker, T. L., Dames, S., Kryskow, P., Christie, B. R., McDonald, S. J., & Shultz, S. R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03329-x · Cited by 5
McHerron, D., Barber, M., Ham, R., Liknaitzky, P., Carter, A., & Gardner, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251377191 · Cited by 4
“20,21 As such, the TherapeuTic advances in psychopharmacology risks of ethical misconduct during PAT are argued to be higher than in conventional psychotherapy.”
Domżalska, M., Kwiatkowska, J., Cichoń, I., & Sokołowska, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-29642-7 · Cited by 4
“In recent randomized controlled trials, psilocybin-assisted psychotherapy has produced rapid and enduring reductions in depressive symptoms, with effects sustained for weeks to months after just one or two sessions 14,15 .”
Dodds, C., Dawson, R. L., Lim, A., Tye, S. J., & Nasrallah, F. A. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396255 · Cited by 4
“176 The findings suggest that psilocybin may be a suitable alternative to SSRIs for the treat-ment of depression symptoms and highlight a need for a clinical trial of greater size and duration.”
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia‐Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117010 · Cited by 5
Mertens, L. J., Betzler, F., Brand, M., Evens, R., Jungaberle, A., Jungaberle, H., Kärtner, L., Majić, T., Schmitz, C. N., Ströhle, A., et al. (2026) · Psychotherapy and Psychosomatics · doi:10.1159/000552272 · Cited by 5
Johansen, L., Liknaitzky, P., Nedeljkovic, M., & Murray, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1265910 · Cited by 6
“Others have investigated more conventional psychological mechanisms, such as experiential avoidance (18) and rumination (19), with these processes also found to be reduced following psychedelicassisted psychotherapy.”
BackgroundMechanisms of integration in psychedelic-assisted therapy
Coverdale, N. S., & Cook, D. J. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0014 · Cited by 6
Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Shah, F. I., Shehzadi, S., Akram, F., Haq, I. U., Javed, B., Sabir, S., Kazim, Y., & Ashfaq, S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00994-7 · Cited by 4
Stutterers’ experiences on classic psychedelics: A preliminary self-report study
Jackson, E. S., Goldway, N., Gerlach-Houck, H., & Gold, N. D. (2024) · Journal of Fluency Disorders · doi:10.1016/j.jfludis.2024.106062 · Cited by 5
Belief change and agnostic frames in psychedelic research and clinical contexts
Yaden, D. B., Nayak, S. M., & Griffiths, R. R. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0008 · Cited by 5
Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Gold, N. D., Pagni, B. A., Petridis, P. D., & Bogenschutz, M. P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0030 · Cited by 4
“46 Trained study staff administered the TLFB at weeks 0, 4, 8, 12, 24, and 36.”
Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report
Fleury, V., Tomkova, E., Chiuvé, S. C., & Penzenstadler, L. E. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241312604 · Cited by 5
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
Exploring Gender-Themed Lysergic Acid Diethylamide Experiences: A Subreddit Analysis
Katkar, R., Perez, A. M., Altinay, M. I., & Barnett, B. S. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0025 · Cited by 4
Leonard, D., & Brooks, T. R. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251330066 · Cited by 4
Tudorancea, I.-M., Stanciu, G. D., Torrent, C., Madero, S., Hriţcu, L., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2499458 · Cited by 4
Christen, S. E., Bekka, E., Schmid, Y., Benowitz, N. L., & Liakoni, E. (2025) · Swiss Medical Weekly · doi:10.57187/s.4346 · Cited by 4
Suggestion Effects in Psychedelics: Confounds and Opportunities
Stein, M. V., & Terhune, D. B. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2501964 · Cited by 7
“A striking example is a recent high-profile trial comparing psilocybin against escitalopram, a selective serotonin reuptake inhibitor (SSRI), in patients with moderate-to-severe depression (Carhart-Harris et al., 2021).”
Psychedelics and mental health: reimagining care through science, insight, and compassion
Mikellides, G., & Kyriazis, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1649929 · Cited by 4
LSD: Mechanisms and relevance to the treatment of depression
Bouloufa, A., Delcourte, S., Delannay, T., Rovera, R., Lau, T., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106407 · Cited by 5
Campolina, A. G., & de Oliveira, M. A. T. (2025) · Healthcare · doi:10.3390/healthcare13212714 · Cited by 5
Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Song, J., Kambari, Y., Amaev, A., Ueno, F., Carmona, E. T., Luca, V. D., Pollock, B. G., Flint, A. J., Husain, M. I., Graff‐Guerrero, A., et al. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111068 · Cited by 5
Griffin, C., & Knight, A. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00333 · Cited by 6
Andersen, K. A. A., Holmøy, B., & Stewart, L. H. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00346 · Cited by 4
Pohořalá, V., Kuchař, M., Spanagel, R., & Bernardi, R. E. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.006 · Cited by 8
Psychedelika in der Psychiatrie: eine offene Debatte
Herwig, U., Schnell, K., Daumann, J., Jungaberle, A., Koller, G., Mertens, L. J., & Borgwardt, S. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2453-0910 · Cited by 4
Exploring serotonergic psychedelics as a treatment for personality disorders
Carrithers, B. M., Roberts, D. E., Weiss, B., King, J. D., Carhart-Harris, R. L., Gordon, A. R., Pagni, B. A., Moreau, M., Ross, S., & Zeifman, R. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110413 · Cited by 4
Self-citationBeesley, V. L., Kennedy, T., Maccallum, F., Ross, M., Harvey, R., Rossell, S. L., Sarris, J. J., Perkins, D., Neale, R. Ε., Bennett–Levy, J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095992 · Cited by 4
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration
Tal, T. B., Pogodin, I., Botvinnik, A., Lifschytz, T., Heresco‐Levy, U., & Lerer, B. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03428-x · Cited by 4
“Signi fi cant bene fi ts in major depressive disorder for 1 – 2 psilocybin (~25 mg) administration sessions have been documented [25, 26].”
Androni, X., Boyd, R. J., Rosenberg, P. B., & Mahairaki, V. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1605051 · Cited by 4
Holborn, T., Schifano, F., Smith, E., & Deluca, P. (2025) · Psychoactives · doi:10.3390/psychoactives4030028 · Cited by 4
“More-over, psychedelics have indicated positive effects in a myriad of areas such as end-of-life anxiety [19–22], depression [23–25] and addiction [26,27].”
Traditional Amazonian medicine in addiction treatment: Qualitative results
O’Shaughnessy, D. M., Sarnyai, Z., Quirk, F. H., & Rodd, R. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100086 · Cited by 4
The Efficacy of Psilocybin in the Treatment of Depression and Anxiety: A Meta-Analysis
Hodge, A. T., Sukpraprut‐Braaten, S., & Strayhan, R. C. (2022) · Current Psychiatry Research and Reviews · doi:10.2174/2666082218666220513142002 · Cited by 5
Unraveling the Mysteries of Mental Illness With Psilocybin
Sottile, R., Singh, H., Weisman, A., & Vida, T. (2022) · Cureus · doi:10.7759/cureus.25414 · Cited by 5
“A double-blind randomized control trial (DB-RDT) was used for the MDD group, comparing the efficacy of psilocybin to escitalopram (similar to the work of CarhartHarris et al., [79] noted above).”
BackgroundMethodInfluentialPsychedelic drugs take on depression
Willyard, C. (2022) · Nature · doi:10.1038/d41586-022-02205-w · Cited by 4
Psychedelics for Alzheimer's Disease Palliative Care
McManus, K. R., Patrick, R. E., Striepe, M. I., Drury, M. J., Ozonsi, R., Forester, B. P., & Weinberg, M. S. (2022) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2022.06.001 · Cited by 5
Electrical spiking of psilocybin fungi
Gandía, A., & Adamatzky, A. (2022) · Communicative & Integrative Biology · doi:10.1080/19420889.2022.2136118 · Cited by 4
“Psilocybin fungi are remarkably famous for inducing mystical-type experiences thanks to tryptamine alkaloids contained in its hyphae, mainly psilocybin, baeocystin and norbaeocystin [4, 5], to which the community of users and a growing pool of scientific evidence grants different potential benefits, such as treating d…”
BackgroundPsychedelics for treating psychiatric disorders: Are they safe?
Thakur, M. (2022) · Current Psychiatry · doi:10.12788/cp.0309 · Cited by 4
Psilocybin-assisted psychotherapy for cancer-related anxiety and depression
Yaniv, D., Ramondetta, L. M., Cohen, L. G., & Amit, M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004659 · Cited by 4
Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance
Osterhold, H. M., & Fernandes‐Osterhold, G. (2023) · Journal of Analytical Psychology · doi:10.1111/1468-5922.12949 · Cited by 5
Potential use of psilocybin drugs in the treatment of depression
Śladowska, K., Kawalec, P., Brzostek, T., & Pilc, A. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2264180 · Cited by 4
“There are no trials directly comparing psilocybin with registered antidepressants, except Psilodep-RCT (NCT03429075) [37,38] including comparison of psilocybin with escitalopram (for details see section 4.1, 4.2 and Table 1).”
BackgroundMethodResultInfluentialThe pharmacological management of treatment-resistant depression: what does the future hold?
Serretti, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2287011 · Cited by 4
“Hundreds of studies have been reported in the last five years, including some clinical trials in depression [4].”
Background(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5048-9 · Cited by 4
Boltaev, U., Park, H. W., Brown, K. R., Delgado, M., Wu, J., Diaz-Pacheco, B. N., Botero-Pinzon, M., He, K., Ahern, E., Goldshmid, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.04.583022 · Cited by 4
“For this purpose, psychedelic compounds have re-emerged as a promising frontier in clinical neuroscience 7–12 .”
BackgroundA dual-receptor model of serotonergic psychedelicsPreprint
Juliani, A., Chelu, V., Graesser, L., & Safron, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.12.589282 · Cited by 8
Kňažek, F., Horák, M., Ocetková, T., Somerlíková, K., Bláhová, B., Plevková, M., Mravčík, V., Chomynová, P., & Kočárová, R. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2177908 · Cited by 3
“…confirming the effects on mental well-being and therapy of mental diseases with ayahuasca, LSD, MDMA, or Psilocybe mushrooms is rapidly increasing (Carhart-Harris et al. 2021; Davis et al. 2021; Domínguez-Clavé et al. 2019; Gasser et al. 2014; Griffiths et al. 2016; Sessa and Fischer 2015; Siegel…”
BackgroundManzano-Núñez, R., Gomez, D. A., Toledo-Mendoza, C., Pérez-Otero, M., Matilla, I. L., Prats, C., Pérez‐López, E. M., Pardo, H., Diaz‐Pellicer, P., de la Torre, R., et al. (2024) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000617 · Cited by 4
Davidson, M., Stanciu, G. D., Rabinowitz, J., Untu, I., Dobrin, R., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2480566 · Cited by 4
“(carhart-Harris et al. 2021). in addition to these clinical findings, preclinical studies further support the potential antidepressant and anxiolytic effects of psychedelics.”
Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns
Bhave, A. (2025) · Journal of Public Policy & Marketing · doi:10.1177/07439156251360774 · Cited by 4
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes
Kishon, R., & Cycowicz, Y. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1637162 · Cited by 3
Psychedelics for substance use disorders: are women being addressed? A scoping review
Nigri, A. W., de Arruda, I. F., Maia, C. G. F., Tófoli, L. F., & Carezzato, F. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104960 · Cited by 3
Psilocybin use in bipolar disorder: A comprehensive review
Do, A., Cloutier, L., Hébert‐Tremblay, L., & Thauvin, C. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120485 · Cited by 4
A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder
Srivastava, A. B., & Gold, M. S. (2025) · Brain Sciences · doi:10.3390/brainsci15111190 · Cited by 3
Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
Rodríguez, L. C., Morera, G., Lupo, S., Davyt, D., Carrera, I., & Dossi, G. H. (2025) · ACS Omega · doi:10.1021/acsomega.5c07092 · Cited by 3
Kerr‐Gaffney, J., Myrtle, S., Askari, F., Bird, C., Modlin, N. L., Young, A. H., & Rucker, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251408769 · Cited by 3
“…depression and anxiety in advanced-stage cancer (Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), major depressive disorder (MDD; Carhart-Harris et al., 2021; Goodwin et al., 2022), alcohol use disorder (Bogenschutz et al., 2022), obsessive compulsive disorder (Moreno et al.,…”
Carlisle, N. A., Simonsson, O., MacCarthy, S., Elliott, M. N., Miller, G. H., Goldberg, S. B., Shallcross, R. A., & Hendricks, P. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-37609-5 · Cited by 4
Kaczmarek, E. S., Rodrigues, N. B., Chisamore, N., Doyle, Z., Meshkat, S., Blainey, M. G., Brudner, R. M., Ali, S., Teopiz, K. M., McIntyre, R. S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121385 · Cited by 3
Zhang, J., Lin, C., Lv, X., Zhao, H., & Wang, X. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.02.011 · Cited by 5
Ziadi, Y., & Park, T. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101605 · Cited by 3
Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis
Kishi, T., Sakuma, K., Hatano, M., Uchida, H., & Iwata, N. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121675 · Cited by 3
Wherefore the Magic? The Evolutionary Role of Psilocybin in Nature
Nicholass, K. J. M., Flis, I., Hanley, M. E., Knight, M. E., Lane, S., Littlejohn, G. R., Thom, M. D. F., Billington, R. A., Boden, R., Cummins, R., et al. (2026) · Ecology and Evolution · doi:10.1002/ece3.73522 · Cited by 4
Recent Developments in the Drug Treatment of Parkinson’s Disease
Leiter, S., Mahlknecht, P., & Poewe, W. H. (2026) · Drugs · doi:10.1007/s40265-026-02327-9 · Cited by 4
“…tract, MAO-B monoamine oxidase B, PDE5 phosphodiesterase 5, SNARE soluble N -ethyl- maleimide-sensitive-factor attachment receptor, 5-HT 5-hydroxytryptamine [161, 162] and an ongoing phase 2 RCT is investigating its possible efficacy also in patients with PD depression (NCT06455293).”
Rowe, T., Hurzeler, T. P., Towers, E., Louie, E., & Morley, K. C. (2026) · Brain and Behavior · doi:10.1002/brb3.71533 · Cited by 4
“…have re-emerged as potential therapeutic tools whereby preliminary efficacy data exist for a range of psychiatric disorders including depression (Carhart-Harris et al. 2021 ), end of life anxiety (Griffiths et al. 2016 ), post-traumatic stress disorder (Mitchell et al. 2023 ), and substance use…”
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
“64 Another potential advantage of PAP is the infrequent need for medication dosing.”
On approximate robust confidence distributions
Bortolato, E., & Ventura, L. (2023) · Econometrics and Statistics · doi:10.1016/j.ecosta.2023.04.006 · Cited by 3
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch, D. E.-W., López, J. P., Dalla, C., Ċastrén, E., Erritzøe, D., Frøkjær, V. G., Lundberg, J., Preller, K. H., Fisher, P. M., & Knudsen, G. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103929 · Cited by 4
“…trials administering psychedelics have been performed, showing early promise for the treatment of psychiatric conditions including depression (Carhart-Harris et al., 2021; Goodwin et al., 2022), cigarette and alcohol addiction (Bogenschutz et al., 2022; Johnson et al., 2017) as well as…”
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.